...
首页> 外文期刊>Cellular immunology >Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy
【24h】

Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy

机译:通过靶向脂肪酸输送蛋白2增强的抗PD-L1肿瘤免疫治疗来调节粘粒源性抑制细胞中的ROS

获取原文
获取原文并翻译 | 示例
           

摘要

Despite the remarkable success and efficacy of immune checkpoint blockade (ICB) therapy against the PD-1/PD-L1 axis, it induces sustained responses in a sizeable minority of cancer patients due to the activation of immunosuppressive factors such as myeloid-derived suppressor cells (MDSCs). Inhibiting the immunosuppressive function of MDSCs is critical for successful cancer ICB therapy. Interestingly, lipid metabolism is a crucial factor in modulating MDSCs function. Fatty acid transport protein 2 (FATP2) conferred the function of PMN-MDSCs in cancer via the upregulation of arachidonic acid metabolism. However, whether regulating lipid accumulation in MDSCs by targeting FATP2 could block MDSCs reactive oxygen species (ROS) production and enhance PD-L1 blockade-mediated tumor immunotherapy remains unexplored. Here we report that FATP2 regulated lipid accumulation, ROS, and immunosuppressive function of MDSCs in tumor-bearing mice. Tumor cells-derived granulocyte macrophage-colony stimulating factor (GM-CSF) induced FATP2 expression in MDSCs by activation of STAT3 signaling pathway. Pharmaceutical blockade of FATP2 expression in MDSCs by lipofermata decreased lipid accumulation, reduced ROS, blocked immunosuppressive activity, and consequently inhibited tumor growth. More importantly, lipofermata inhibition of FATP2 in MDSCs enhanced anti-PD-L1 tumor immunotherapy via the upregulation of CD107a and reduced PD-L1 expression on tumor-infiltrating CD8(+) T-cells. Furthermore, the combination therapy blocked MDSC's suppressive role on T-cells thereby enhanced T-cell's ability for the production of IFN-gamma. These findings indicate that FATP2 plays a key role in modulating lipid accumulation-induced ROS in MDSCs and targeting FATP2 in MDSCs provides a novel therapeutic approach to enhance anti-PD-L1 cancer immunotherapy.
机译:尽管针对PD-1/PD-L1轴的免疫检查点阻断(ICB)疗法取得了显著的成功和疗效,但由于免疫抑制因子(如骨髓源性抑制细胞(MDSC))的激活,它在相当一部分癌症患者中诱导了持续的反应。抑制MDSCs的免疫抑制功能对于癌症ICB治疗的成功至关重要。有趣的是,脂质代谢是调节骨髓间充质干细胞功能的关键因素。脂肪酸转运蛋白2(FATP2)通过上调花生四烯酸代谢赋予PMN-MDSCs在癌症中的功能。然而,通过靶向FATP2调节骨髓间充质干细胞中的脂质积聚是否可以阻断骨髓间充质干细胞活性氧(ROS)的产生并增强PD-L1阻断介导的肿瘤免疫治疗仍有待探索。在此,我们报告了FATP2调节荷瘤小鼠骨髓间充质干细胞的脂质积累、活性氧和免疫抑制功能。肿瘤细胞源性粒细胞-巨噬细胞集落刺激因子(GM-CSF)通过激活STAT3信号通路诱导MDSCs中FATP2的表达。lipofermata药物阻断MDSCs中FATP2的表达可减少脂质积累,减少ROS,阻断免疫抑制活性,从而抑制肿瘤生长。更重要的是,脂质体对MDSCs中FATP2的抑制通过上调CD107a和降低肿瘤浸润性CD8(+)T细胞上的PD-L1表达来增强抗PD-L1肿瘤免疫治疗。此外,联合治疗阻断了MDSC对T细胞的抑制作用,从而增强了T细胞产生IFN-γ的能力。这些研究结果表明,FATP2在调节MDSCs中脂质积聚诱导的ROS中起关键作用,并且在MDSCs中靶向FATP2为增强抗PD-L1癌症免疫治疗提供了一种新的治疗方法。

著录项

  • 来源
    《Cellular immunology》 |2021年第1期|共17页
  • 作者单位

    Chinese Acad Sci Guangdong Immune Cell Therapy Engn &

    Technol Res Ctr Prot &

    Cell Based Drugs;

    Chinese Acad Sci Guangdong Immune Cell Therapy Engn &

    Technol Res Ctr Prot &

    Cell Based Drugs;

    Chinese Acad Sci Guangdong Immune Cell Therapy Engn &

    Technol Res Ctr Prot &

    Cell Based Drugs;

    Chinese Acad Sci Guangdong Immune Cell Therapy Engn &

    Technol Res Ctr Prot &

    Cell Based Drugs;

    Chinese Acad Sci Guangdong Immune Cell Therapy Engn &

    Technol Res Ctr Prot &

    Cell Based Drugs;

    Chinese Acad Sci Guangdong Immune Cell Therapy Engn &

    Technol Res Ctr Prot &

    Cell Based Drugs;

    Shenzhen Childrens Hosp Dept Hematol &

    Oncol Shenzhen 518036 Peoples R China;

    Dongguan Enlife Stem Cell Biotechnol Inst Dongguan 523000 Peoples R China;

    Dongguan Enlife Stem Cell Biotechnol Inst Dongguan 523000 Peoples R China;

    Chinese Univ Hong Kong Sch Biomed Sci Hong Kong Peoples R China;

    Chinese Acad Sci Guangdong Immune Cell Therapy Engn &

    Technol Res Ctr Prot &

    Cell Based Drugs;

    Chinese Acad Sci Guangdong Immune Cell Therapy Engn &

    Technol Res Ctr Prot &

    Cell Based Drugs;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 细胞生物学;
  • 关键词

    MDSCs; Lipid metabolism; ROS; FATP2; Anti-PD-L1 tumor immunotherapy;

    机译:MDSCS;脂质代谢;ROS;FATP2;抗PD-L1肿瘤免疫疗法;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号